TruAlt Bioenergy announces an acquisition

Transaction Assessment: Badami Unit (Unit 5) Divestment

Verdict The transaction is structured as a clean exit from the Badami unit (Unit 5) rather than an ongoing operational partnership ^[1]. TruAlt Bioenergy has approved the sale of the entire undertaking—including land, buildings, plant, machinery, and movable assets—to Onkar Agro Sugars & Energy Private Limited via a slump sale as a going concern for Rs 171 Crores ^[1]. No ongoing operational, supply, or off-take obligations were reported in the regulatory disclosure ^[1].

Key Evidence and Transaction Terms

• Scope of Divestment: The transaction covers the sale of Unit 5 situated at Muttalageri Village, Badami Taluka, Karnataka, encompassing land, building, plant and machinery, and movable assets forming part of the facility ^[1].
• Consideration: Total aggregate consideration is Rs 171 Crores ^[1].
• Absence of Retained Commitments: The intimation under Regulation 30 of SEBI (LODR) Regulations contains no terms establishing retained equity interest, joint operating agreements, tolling arrangements, or post-sale off-take agreements ^[1].

Strategic & Financial Implications

• Zero Revenue Impact: Unit 5 contributed 0% to TruAlt Bioenergy's revenue for the fiscal year ended March 31, 2026 ^[1]. Divestment does not create supply shortfalls or contractually lock the company into buying/selling output from the facility post-close.
• Asset Clean-up: Severing operational involvement allows full divestment of a non-core facility to monetize tied-up capital and reduce debt overhead ^[1].

Execution Caveats

• Pending Definitive Agreements: The terms reflect the board-approved framework and remain subject to the execution of definitive agreement(s), customary closing adjustments, conditions precedent, and required regulatory/statutory approvals ^[1].
• Disclosure Boundary: If subsequent definitive documentation includes ancillary covenants or transition arrangements, those details have not yet been reported in the initial disclosure ^[1].

Executive Summary

The Rs 171 Crore divestment of Unit 5 (Badami) ^[1] provides immediate balance sheet deleveraging, reducing TruAlt Bioenergy's consolidated net debt of Rs 1,557.50 Crores (Q4 FY26 baseline) ^[2] by up to 11.0% to a pro-forma Rs 1,386.50 Crores (derived).

Regarding capital expenditure, the company has not disclosed a specific numeric allocation of these proceeds toward stated capex plans for the current fiscal year ^[1]. Instead, the primary explicit allocation is debt repayment—specifically discharging approximately Rs 135 Crores of outstanding term debt ^[1].

---

Net Debt Impact Analysis

As of Q4 FY26, TruAlt Bioenergy carried significant leverage, with consolidated gross debt of Rs 1,645.80 Crores ^[3] and net debt of Rs 1,557.50 Crores ^[2].

• Net Deleveraging Impact: Ingesting the Rs 171 Crore cash consideration ^[1] reduces consolidated net debt from Rs 1,557.50 Crores ^[2] to Rs 1,386.50 Crores (derived), representing an 11.0% reduction in net debt.
• Interest Cost Relief: Earmarking approximately Rs 135 Crores of proceeds to extinguish an outstanding term loan from IREDA ^[1] directly addresses high-cost borrowing. This provides operating cash flow relief by mitigating annual interest expenses, which totaled Rs 160.02 Crores TTM on a consolidated basis in Q4 FY26 ^[7].

---

Allocation Toward Stated Capital Expenditure Plans

• Primary Stated Allocation (Debt Discharge): Management explicitly prioritized debt reduction over new capital spend in its transaction intimation, allocating approximately 79% (Rs 135 Crores) of the Rs 171 Crore total proceeds to clear the IREDA term loan ^[1].
• Disclosure Gap on FY Capex Breakdown: The company has not reported a specific project-wise or current-year numeric capex allocation for the remaining Rs 36 Crore balance (or total proceeds) ^[1].
• Strategic Asset Rationalization: The divested Unit 5 in Badami, Karnataka represented 10.53% of the company's net worth as of March 31, 2026, but contributed 0% of revenues during FY26 ^[1]. Management qualitatively indicated that monetizing this non-core asset enables the reallocation of capital toward core high-growth opportunities ^[1], though exact capital expenditure guidance for the current fiscal year remains unquantified in regulatory announcements.